Hikma Looking For Joint Ventures In Middle East Emerging Markets

Meanwhile, in Algeria Hikma is now the largest generic drug provider by value with a 7% market share. Its sales growth has been attributed to a diverse pharmaceutical offering and a focus on cardiovascular medicines, similar to its strategy in Saudi Arabia, where it now ranks as the fourth largest drugmaker by market share.

To read the full article, please choose one of the following options: